211 
Market Cap
Stock Chart
CSLltd - 30 day Poll
Recent BLOGS About CSL Add New
Latest Company News
|
International Phase I Trial Results of Recombinant Fusion Protein Linking ...
MarketWatch (press release) - Feb 2, 2012 ST. GALLEN, Switzerland, Feb. 2, 2012 /PRNewswire via COMTEX/ -- CSL Behring today announced the results of a Phase I study evaluating recombinant fusion protein linking coagulation Factor IX with albumin (rIX-FP) in patients with severe hemophilia B.
|
|
IG Markets Afternoon thoughts
Scoop.co.nz (press release) - Feb 2, 2012 Across Asia, markets have responded to the gains seen across European and US markets. Risk is currently in favour as broadly positive manufacturing prints globally further consolidated expectations that fears over a global economic slowdown are ...
|
|
Australian Stock Market Leads - 30 January 2012
International Business Times AU - Jan 29, 2012 By Christine Gaylican | January 30, 2012 10:08 AM EST The Australian stock market is set to mildly rebound on Monday's trading in spite the weak leads from US and European markets.
|
|
This is not the time to abandon quality shares
The Motley Fool - Jan 25, 2012 By Mike King - Tuesday, January 24th, 2012 Selling quality companies like Woolworths Limited (ASX: WOW) or CSL Limited (ASX: CSL)?
|
|
Midday: Aus shares gain 0.5%
Finance News Network - Jan 24, 2012 Lifted with a positive lead from European markets the Australian share market has gained 0.5 per cent at noon. Stronger commodity prices overnight have boosted the miners and energy stocks as the sectors continues to absorb production reports today.
|
|
Kew man donates blood for more than 55 years
Leader News - Jan 22, 2012 AFTER more than 55 years of donating blood, Kew's Peter Schiff is still a happy little vegemite. The “almost retired” 76-year-old has saved more than 1600 lives through more than 560 blood, plasma and platelet donations.
|
|
Cytomedix Appoints Cathryn Hope as Vice President of Marketing
MarketWatch (press release) - Jan 17, 2012 GAITHERSBURG, MD, Jan 17, 2012 (MARKETWIRE via COMTEX) -- Cytomedix, Inc. /quotes/zigman/3795200 CMXI -3.70% (the "Company"), a leading developer of biologically active regenerative therapies for wound care, inflammation and angiogenesis, ...
|
|
one2free Introduces First-Ever Prepaid BlackBerry Service in Hong Kong
IEWY News - Jan 12, 2012 Hong Kong - one2free today announced the launch of the first-ever prepaid BlackBerry® service for customers in Hong Kong. Without the need for a contract or registration, customers can now enjoy BlackBerry service for as little as HK$120 for seven days ...
|
Website
Videos related to CSL
- Biotech/Life Sciences in Melbourne
- Is there value in the healthcae stocks?
- GSK (CSL competition) gets it flu vaccine approved for children, Boston Scientific and more
- CSL swine flu vaccine requires only 1 dose
- The Centers for Disease Control offered an update on the H1N1, also known as swine flu, virus.
Company Profile
Major facilities in Australia, Germany, Switzerland and the US, CSL has over 10,000 employees working in 27 countries.
Net sales of $1,129 million for the six months ended June 30, 2009
Plasma Products: Human plasma is used to produce a wide range of life-saving medicines. CSL's various businesses support all aspects of the process from the collection and testing of donated plasma through to the production of a range of plasma-derived products.
The key businesses involved with plasma products include: CSL Behring is a global provider of plasma-derived & recombinant products. We operate one of the world's largest plasma collection networks through CSL Plasma CSL Bioplasma is the chosen national plasma fractionator of Australia, New Zealand, Hong Kong, Malaysia, Singapore and Taiwan.
CSL also manufacture and market in vitro diagnostic products through Immunohaematology Vaccines & Pharmaceuticals. The company manufactures and provide influenza vaccine globally.
In Australia and New Zealand, CSL Biotherapies also markets a comprehensive range of vaccines and antivenoms as well as a range of pharmaceutical products supplied by other manufacturers.
Research & Development: Activities at CSL are focused on new product development, life-cycle management and safety of an extensive product portfolio. CSL invests in the development of protein-based medicines for treating serious human diseases. Medicines can be made from plasma, traditional biological sources or using recombinant biotechnology.
Competition:
- Talecris